← Back to Screener
Coeptis Therapeutics Holdings Inc. Common Stock (COEP)
Price$9.31
Value ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-57.60%
Price vs S&P 500 (4W)-46.64%
VGM Score24.38
Market Capitalization$102.06M
All Metrics
Book Value / Share (Quarterly)$0.12
P/TBV (Annual)8.24x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.20
Price vs S&P 500 (YTD)-45.40%
Gross Margin (TTM)86.75%
Net Profit Margin (TTM)-800.39%
EPS (TTM)$-0.88
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-0.88
EPS (Annual)$-0.83
ROI (Annual)-391.00%
Gross Margin (Annual)100.00%
Cash / Share (Quarterly)$0.04
ROA (Last FY)-263.49%
EBITD / Share (TTM)$-0.85
ROE (5Y Avg)-753.87%
Operating Margin (TTM)-945.28%
Cash Flow / Share (Annual)$-0.20
P/B Ratio23.66x
P/B Ratio (Quarterly)6.20x
Net Income / Employee (Annual)$-4,253,300
EV / Revenue (TTM)70.90x
Net Interest Coverage (TTM)-107.66x
ROA (TTM)-296.37%
EV / EBITDA (TTM)77.93x
EPS Incl Extra (Annual)$-0.83
Current Ratio (Annual)1.76x
Quick Ratio (Quarterly)1.68x
3-Month Avg Trading Volume0.09M
52-Week Price Return2.76%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.15
P/S Ratio (Annual)1360.81x
Asset Turnover (Annual)0.01x
52-Week High$21.41
EPS Excl Extra (Annual)$-0.83
26-Week Price Return-41.67%
Quick Ratio (Annual)1.68x
13-Week Price Return-25.22%
Total Debt / Equity (Annual)0.26x
Current Ratio (Quarterly)1.76x
Enterprise Value$101.72M
Asset Turnover (TTM)0.10x
Book Value / Share Growth (5Y)-16.26%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-17932.37%
Cash / Share (Annual)$0.04
3-Month Return Std Dev89.86%
Net Income / Employee (TTM)$-4,199,600
ROE (Last FY)-492.97%
Net Interest Coverage (Annual)-3.81x
EPS Basic Excl Extra (Annual)$-0.83
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.26x
EPS Incl Extra (TTM)$-0.88
ROI (TTM)-445.55%
P/S Ratio (TTM)74.88x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.25
Price vs S&P 500 (52W)-25.45%
Year-to-Date Return-34.67%
5-Day Price Return3.67%
EPS Normalized (Annual)$-0.83
ROA (5Y Avg)-220.71%
Net Profit Margin (Annual)-17932.37%
Month-to-Date Return-41.67%
Cash Flow / Share (TTM)$-2.69
EBITD / Share (Annual)$-0.81
Operating Margin (Annual)-18773.29%
LT Debt / Equity (Annual)0.03x
ROI (5Y Avg)-392.09%
LT Debt / Equity (Quarterly)0.03x
EPS Basic Excl Extra (TTM)$-0.88
P/TBV (Quarterly)7.89x
P/B Ratio (Annual)6.20x
Pretax Margin (TTM)-900.72%
Book Value / Share (Annual)$0.12
Price vs S&P 500 (13W)-34.97%
Beta0.39x
Revenue / Share (TTM)$0.00
ROE (TTM)-641.09%
52-Week Low$6.80
vGradeF
mGradeC
vgmGradeD
Show chart for
Analyst Recommendations
Nov 2024
Dec 2024
Jan 2025
Feb 2025
2.17
2.17
2.17
2.17
Industry Peers — Finance Services(152)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
COEPCoeptis Therapeutics Holdings Inc. Common Stock | F | — | C | $9.31 |
| AXPAmerican Express Company | D | B | C | $313.54 |
| NUNu Holdings Ltd. | D | B | C | $12.99 |
| COINCoinbase Global, Inc. Class A Common Stock | D | C | C | $182.61 |
| MSTRStrategy Inc Common Stock Class A | D | D | C | $149.78 |
| CRCLCircle Internet Group, Inc. | F | C | B | $104.97 |
| SYFSYNCHRONY FINANCIAL | B | C | C | $70.82 |
| SOFISoFi Technologies, Inc. Common Stock | D | B | B | $18.58 |
| IRENIREN Limited Ordinary Shares | F | B | A | $65.33 |
| HUTHut 8 Corp. Common Stock | F | A | A | $132.38 |
| WULFTeraWulf Inc. Common Stock | F | B | A | $25.66 |
About
Coeptis Therapeutics develops cell therapy platforms for cancer patients. The company's pipeline includes SNAP-CAR, a multi-antigen CAR T technology licensed from the University of Pittsburgh, and CD38-GEAR-NK, a cell therapy candidate, along with a companion diagnostic. Coeptis collaborates with VyGen-Bio and the Karolinska Institutet on its CD38-targeted oncology programs.